Immunotherapy Advances in Multiple Myeloma - Curetalks

Hear Talk Audio


Immunotherapy Advances in Multiple Myeloma

Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody therapies. antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. We are talking to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma. 

Panelists

Talk Recorded on Apr 18, 2017, 06:00 pm EST </> Embed
<iframe src="https://www.curetalks.com/event-embed/942" id="frame" frameborder="0" scrolling="no" style="width: 100%; overflow: hidden; min-height: 500px;" ></iframe>

Submit a question for the panelists or leave a comment below.

Your email address will not be published. Required fields are marked *

Comments/Questions

  1. P

    Most of the multiple myeloma patients become resistant to existing therapies or relapse. How long do you predict, the effects of a particular immunotherapy will last on patients before they start showing resistance.